News

Metagenomics, the study of genetic material extracted directly from the stool microbiomes of people with PD and neurologically healthy control participants, was used by researchers at the University of Alabama at Birmingham in the US. The gut microbiome is engaged...

Innovative technology could help people with Type 1 diabetes who can't control their condition, and it will be made available to them. Additionally, the aid is going to be provided with little human involvement. With the technology being referred to...

When most people hear the term ’cloning’, they immediately recollect the story of Dolly, the first sheep to be cloned. Out of 277 embryos, she was the only viable fetus. Dolly lived for seven years. Her creation caused huge...

According to EY's 2023 M&A Firepower report, the life sciences sector has record levels of deal-making Firepower, which measures a company's ability to undertake M&A on the strength of its balance sheet. M&A activity worldwide in 2022 In the first eleven...

The AMR Action Fund, a public-private partnership investing in biotech companies developing antimicrobials, has invested in BioVersys AG, a clinical-stage company based in Basel, Switzerland. The transaction marks the Fund's first investment in Europe and is an important step...

Bristol Myers Squibb has exercised its option under a research collaboration with Dragonfly Therapeutics, Inc, to enter into an exclusive license for a sixth TriNKET Immunotherapy drug candidate, bringing the total drug candidates licensed by BMS to seven including...

Catalent and Sarepta Therapeutics have signed a commercial supply agreement for Catalent to manufacture delandistrogene moxeparvovec (SRP-9001), Sarepta’s most advanced gene therapy candidate for the treatment of Duchenne muscular dystrophy (DMD). The agreement also structures how Catalent may support...